Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emergent BioSolutions's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was €0.18.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €0.86.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Emergent BioSolutions's EPS without NRI or its related term are showing as below:
During the past 13 years, Emergent BioSolutions's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 61.90% per year. The lowest was -18.80% per year. And the median was 21.20% per year.
STU:ER4's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.65 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Emergent BioSolutions (STU:ER4) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Emergent BioSolutions EPS without NRI Related Terms
Emergent BioSolutions EPS without NRI Historical Data
* Premium members only.
The historical data trend for Emergent BioSolutions's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ER4 vs ELTP, NIKA, EOLS: EPS without NRI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emergent BioSolutions PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.86
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions (STU:ER4) has a EPS without NRI of €0.86 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Emergent BioSolutions and its competitors. According to the industry distribution chart, Emergent BioSolutions ranks #999999 out of 788 companies in the Drug Manufacturers industry.
Is Emergent BioSolutions' EPS without NRI too high?
Emergent BioSolutions' current EPS without NRI is €0.86. Based on the distribution chart, Emergent BioSolutions ranks #999999 out of 788 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Emergent BioSolutions has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' EPS without NRI compare to ELTP and NIKA?
According to the Drug Manufacturers industry distribution chart, Emergent BioSolutions ranks #999999 out of 788 companies for EPS without NRI. This places Emergent BioSolutions in the lower half of its industry. The industry median EPS without NRI is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.65, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Emergent BioSolutions and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emergent BioSolutions's current EPS without NRI is €0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (STU:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.12, compared to a current price of €6.68 — trading 62.1% above its estimated fair value. The current EPS without NRI is €0.86. Emergent BioSolutions' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Emergent BioSolutions (STU:ER4), the current EPS without NRI is €0.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (STU:ER4) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued.
The current stock price of €6.68 is trading 62.1% above its estimated GF Value™ of €4.12.
GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.
Key valuation signals for STU:ER4:
EPS without NRI: €0.86
GF Value™: €4.12 vs. price of €6.68 (62.1% above fair value)
No single metric tells the full story. See the STU:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
61GF Score
Get the complete analysis for STU:ER4
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ER4 has been successfully added to your 
